Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 77% Improvement Relative Risk Ventilation 82% Clinical deterioration 87% c19colchicine.com Deftereos et al. NCT04326790 Colchicine RCT LATE Favors colchicine Favors control
Deftereos, 105 patient colchicine late treatment RCT: 77% lower mortality [p=0.19], 82% lower ventilation [p=0.1], and 87% lower progression [p=0.05] https://c19p.org/deftereos
copied to clipboard
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
Deftereos et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2020.13136
24 Jun 2020    Source   PDF   Share   Tweet
RCT with 55 patients treated with colchicine and 50 control patients, showing lower mortality and ventilation with treatment. NCT04326790.
risk of death, 77.3% lower, RR 0.23, p = 0.19, treatment 1 of 55 (1.8%), control 4 of 50 (8.0%), NNT 16.
risk of mechanical ventilation, 81.8% lower, RR 0.18, p = 0.10, treatment 1 of 55 (1.8%), control 5 of 50 (10.0%), NNT 12.
risk of clinical deterioration, 87.4% lower, RR 0.13, p = 0.046, treatment 1 of 55 (1.8%), control 7 of 50 (14.0%), NNT 8.2, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Deftereos et al., 6/24/2020, Randomized Controlled Trial, Greece, Europe, peer-reviewed, 49 authors, trial NCT04326790.
All Studies   Meta Analysis
This PaperColchicineAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit